OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.

Date publication

juillet 2021

Journal

European urology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEIFFERT Didier

Tous les auteurs :
Supiot S, Vaugier L, Pasquier D, Buthaud X, Magné N, Peiffert D, Sargos P, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Morvan C, Campion L, Blanc-Lapierre A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34247896

Résumé

Oligorecurrent pelvic nodal relapse in prostatic cancer is a challenge for regional salvage treatments. Androgen depriving therapies (ADTs) are a mainstay in metastatic prostate cancer, and salvage pelvic radiotherapy may offer long ADT-free intervals for patients harboring regional nodal relapses.

Mots clés

Choline, Fluciclovine, Intensity-modulated radiotherapy, Lymphadenectomy, Oligometastases, Oligorecurrent, Pelvic radiotherapy, Positron-emission tomography prostate-specific membrane antigen, Prostate bed irradiation, Prostate cancer, Salvage, Stereotactic ablative radiotherapy, Stereotactic body radiotherapy, Stereotactic radiotherapy

Référence

Eur Urol. 2021 Jul 8;: